TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06552923

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ECHO Tele-Education
Description: A common curriculum was developed that covered best practices in multidisciplinary diabetes care for the primary care setting that was guided by the ADA Clinical Care. guidelines. FQHCs attended one-hour tele-ECHO sessions twice a month for 6-months.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ECHO Tele-Education
Description: A common curriculum was developed that covered best practices in multidisciplinary diabetes care for the primary care setting that was guided by the ADA Clinical Care. guidelines. FQHCs attended one-hour tele-ECHO sessions twice a month for 6-months.
Study: NCT06164314

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: In Dex group, dexmedetomidine will continue to be used during and after surgery, with a infusion of 0.4ug/kg/ h from anesthesia induction to dural closure, and then 0.08ug/kg/ h to 48 hours postoperatively.In placebo group, equivalent normal saline will be injected during operation, and the intravenous analgesia pump will not contain dexmedetomidine after operation

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Dexmedetomidine
Description: In Dex group, dexmedetomidine will continue to be used during and after surgery, with a infusion of 0.4ug/kg/ h from anesthesia induction to dural closure, and then 0.08ug/kg/ h to 48 hours postoperatively.In placebo group, equivalent normal saline will be injected during operation, and the intravenous analgesia pump will not contain dexmedetomidine after operation
Study: NCT04858542

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Educational Vocal Health Modules
Description: We have developed four educational health modules (total duration of approximately 30 minutes). First, these modules explain how masks impact communication and voice, then they describe health strategies to improve communication and voice, and finally, they give real-life examples of how the strategies can be implemented into the work setting.
Study: NCT04669028

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NE3107
Description: NE3107 is an investigational orally bioavailable, blood-brain barrier permeable anti-inflammatory agent with a new mechanism of action targeting multiple mechanisms of pathology in Alzheimer's disease.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: capsules that do not contain NE3107
Study: NCT05512858

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: sensory room
Description: the room has dimmed lighting, sensing games, essential oils, picture books and cookbooks, two heavy blankets (weighing 9 kg and 11 kg), a rocking chair, and a vestibular plate. The occupational therapist will accompany the first entry into the room to create a sensory profile, adjust and instruct on the means, and write a treatment card. The treatment card will record the patient's choices and instructions for arranging the room, and it will be used by the staff members who will admit the patient as needed. Each patient will be able to stay in the room for self-treatment according to the individual treatment card prepared at the first sensory room treatment, up to half an hour.
Study: NCT04834908

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Equine COVID-19 Antiserum
Description: Equine COVID-19 antiserum is a polyclonal antibody and it contains Equine COVID-19 immune globulin G.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard of care
Description: Standard of care for COVID 19 infection based on the current guidelines and institutional practice will be provided

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard of care
Description: Standard of care for COVID 19 infection based on the current guidelines and institutional practice will be provided
Study: NCT05296317

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dense dose epirubicin-cyclophosphamide chemotherapy and G-CSF (filgrastim, lenograstim)
Description: - Arm 1: 2 cycles of chemotherapy with administration of G-CSF (filgrastim or lenograstim) on D2, D4 to D7 or D8..~Realization of blood sampling at D1, D4, D8 and D14

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dense dose epirubicin-cyclophosphamide chemotherapy with administration of peg-G-CSF (pegfilgrastim)
Description: - Arm 2: 2 cycles of chemotherapy with administration of peg-G-CSF (pegfilgrastim) on D2.~Realization of blood sampling at D1, D4, D8 and D14
Study: NCT06199804

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Toy Hygiene Training
Description: The training was given to the mothers in 2 sessions (morning and afternoon), each lasting approximately 30 minutes, accompanied by the Toy Hygiene Guide. The sessions were presented face to face in the mother's room in the form of explaining, showing, question and answer and power point, at a time convenient for the mother and the child, outside the morning and afternoon treatment and care hours. After the first session was completed, an appointment was made with the mother for the afternoon session. In the second session, the information in the book that was not given in the first session was presented to the mothers face to face in the mother's room, outside the treatment and care hours, at a time convenient for the mother and the child. After the training was completed, a final five-minute discussion was held with the mothers in the form of a general question and answer session. The training book was given to the mothers in the experimental group on the first day.
Study: NCT06302803

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intermittent fasting plus time-restricted eating
Description: Participants in the mTRE group will be instructed to eat during a window of 8 h (8 am to 4 pm) 5 days and fast (approximately 500-600 kcal per day) 2 days per week.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Calorie restriction
Description: Participants will follow receive a diet of 1500-1800kcal/d for men and 1200-1500kcal/d for women, without restriction on eating time.
Study: NCT04755764

Intervention type: DRUG
Intervention: Labetalol
Description: Beta blocker

Intervention type: DRUG
Intervention: Atenolol
Description: Beta blocker

Intervention type: DRUG
Intervention: Nifedipine
Description: Calcium channel blocker
Study: NCT06266559

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Chang Geng Healthy Drink
Description: Chang Geng Healthy Drink consists of Zingiberis Rhizoma, Codonopsis pilosula, Atractylodis Macrocephalae Rhizoma, Poria cocos, Citri reticulatae Pericarpium

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Chang Geng Healthy Drink
Description: Chang Geng Healthy Drink consists of Zingiberis Rhizoma, Codonopsis pilosula, Atractylodis Macrocephalae Rhizoma, Poria cocos, Citri reticulatae Pericarpium
Study: NCT06357845

Intervention type: OTHER
Group type: OTHER
Intervention: Survey
Description: Participants will complete a brief web-based survey asking about their experiences related to the February 3, 2023 train derailment, health experiences and concerns following the derailment, and background information regarding their health history. The survey will last approximately 15 minutes.

Intervention type: OTHER
Group type: OTHER
Intervention: Biological specimen collection
Description: Participants may possibly contribute biospecimens such as blood, spit, hair, and/or toenail clippings. Participants will be asked which samples they are interested in providing. Participants will receive a specific sample collection kit based on their selection. For blood samples, participants will receive a mailed collection kit at their mailing address. A member of the research team will reach out to schedule blood sample collection, which may take place at home with a trained phlebotomist or at a designated collection site. A total of 1-2 teaspoons of blood (5-10 milliliters) will be collected at a one-time blood draw. For either saliva, hair, and/or toenail clippings, participants will be sent a sample collection kit and receive instructions at their mailing address. This kit also includes a return mailing envelope. Participants will provide the selected samples in the collection kits, place them in the return mailing envelope, and send them back to the research team.

Intervention type: OTHER
Group type: OTHER
Intervention: Communications about study updates and future research opportunities
Description: By consenting to participate in this study, the research team will send updates about the research results and any additional study opportunities to participants.

Intervention type: OTHER
Group type: OTHER
Intervention: Qualitative interview
Description: A total of 40 study participants will be recruited to participate in a 90-minute interview with open-ended questions. The interviews will be video and audio-recorded.
Study: NCT05915611

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Combined physical and psychological intervention
Description: Physical therapy components will include splinting, tendon and nerve gliding exercises.~Psychological components will include cognitive-behavioral therapy (CBT), delivered in individual sessions, targeting pain catastrophizing and fear of movement.~Participants will attend 2 physical therapy sessions and one CBT session per week. for a period of 12 weeks

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard care
Description: Participants will be asked to wear a prefabricated wrist splint during the night and during strenuous activity. Also, they will receive tendon and nerve gliding exercises
Study: NCT04651205

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: vitamin B1 and magnesium supplements
Description: vitamin B1 - 100 mg/day magnesium - 400 mg/day

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: vitamin B1 and magnesium supplements
Description: vitamin B1 - 100 mg/day magnesium - 400 mg/day
Study: NCT05362357

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: iSTART Web-app
Description: 30-day substance prevention web-app for students at a Hispanic Serving Institution.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: iSTART Web-app
Description: 30-day substance prevention web-app for students at a Hispanic Serving Institution.
Study: NCT04408677

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Zilia Ocular
Description: Measurement of the oxygen saturation in the eye fundus

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Zilia Ocular
Description: Measurement of the oxygen saturation in the eye fundus

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Zilia Ocular
Description: Measurement of the oxygen saturation in the eye fundus
Study: NCT04734262

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sitravatinib
Description: Sitravatinib QD PO Sitravatinib is a small molecule inhibitor of receptor tyrosine kinases

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sitravatinib
Description: Sitravatinib QD PO Sitravatinib is a small molecule inhibitor of receptor tyrosine kinases

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sitravatinib
Description: Sitravatinib QD PO Sitravatinib is a small molecule inhibitor of receptor tyrosine kinases

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tislelizumab
Description: Tislelizumab Q3W IV Tislelizumab is a programmed death receptor-1 (PD-1) blocking antibody

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tislelizumab
Description: Tislelizumab Q3W IV Tislelizumab is a programmed death receptor-1 (PD-1) blocking antibody

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tislelizumab
Description: Tislelizumab Q3W IV Tislelizumab is a programmed death receptor-1 (PD-1) blocking antibody

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab-paclitaxel
Description: Nab-paclitaxel D1, D8 Q3W IV Nab-paclitaxel is a chemotherapy drug which combines the chemotherapy drug paclitaxel with albumin
Study: NCT04824703

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxygen
Description: * Decreasing fraction of inspired oxygen and its effect on mortality and myocardial function~* administered by invasive mechanical ventilation with fraction of inspired oxygen between 0.21 and 1

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Oxygen
Description: * Decreasing fraction of inspired oxygen and its effect on mortality and myocardial function~* administered by invasive mechanical ventilation with fraction of inspired oxygen between 0.21 and 1
Study: NCT04861311

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness/Acceptance-Based Smartphone App (MABSA) Intervention
Description: The intervention is based on the principles of Acceptance and Commitment Therapy (ACT). Therefore, the intervention is an ACT-based smartphone app delivered for 6 weeks in which participants will be applying the mindfulness and acceptance exercises embedded in the app. The mindfulness and acceptance exercises are audio-guided mindfulness meditations and video lessons about ACT.
Study: NCT04766151

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Transdermal glyceryl trinitrate 10mg patches
Description: Transdermal patches applied to skin 30 minutes before cardiac catheterization

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo patches
Description: Transdermal placebo patches applied to skin 30 minutes before cardiac catheterization
Study: NCT05813288

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexpramipexole Dihydrochloride
Description: Oral administration of dexpramipexole tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexpramipexole Dihydrochloride
Description: Oral administration of dexpramipexole tablet

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral administration of placebo tablet
Study: NCT06428435

Intervention type: DIAGNOSTIC_TEST
Intervention: Vision Test
Description: Remote vision testing via digital screen

Intervention type: DIAGNOSTIC_TEST
Intervention: Vision Test
Description: Remote vision testing via digital screen
Study: NCT04990375

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: tDCS
Description: 5 sessions of 20-minute tDCS at 2 mA over the dorsolateral prefrontal cortex (35cm² sponge)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: tDCS
Description: 5 sessions of 20-minute tDCS at 2 mA over the dorsolateral prefrontal cortex (35cm² sponge)

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: tDCS
Description: 5 sessions of 20-minute tDCS at 2 mA over the dorsolateral prefrontal cortex (35cm² sponge)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: tDCS
Description: 5 sessions of 20-minute tDCS at 2 mA over the dorsolateral prefrontal cortex (35cm² sponge)
Study: NCT06028425

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LOXO-783
Description: Administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LOXO-783
Description: Administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LOXO-783
Description: Administered orally.
Study: NCT06287372

Intervention type: OTHER
Intervention: Cardioplegic solution
Description: Patients were randomly assigned to undergo surgery using one of two methods for myocardial protection

Intervention type: OTHER
Intervention: Cardioplegic solution
Description: Patients were randomly assigned to undergo surgery using one of two methods for myocardial protection
Study: NCT06348303

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metaxalone m640 mg oral tablet
Description: Metaxalone partially micronized 640 mg tablet

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metaxalone 800 mg oral tablet
Description: Metaxalone non-micronized 800 mg oral tablet
Study: NCT06183281

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CBT, Mindfulness, and Movement
Description: Blended CBT, mindfulness, and movement delivered through a mobile app and supported by a weekly telehealth pain management coach.
Study: NCT05572346

Intervention type: OTHER
Intervention: Home-based telerehabilitation program delivered through digital devices
Description: To evaluate the effects of digital home-based telerehabilitation program on functional and spirometric measures as well as on quality of life in patients with chronic respiratory disease
Study: NCT04902898

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Circumcision in adults using sterile single-use circular stapling device
Description: Circumcision in adults using sterile single-use circular stapling device CIRCCURER II (Jiangxi Langhe Medical Instrument Co., Ltd., Guangzhou, China)
Study: NCT04783974

Intervention type: DEVICE
Intervention: Dental implants
Description: Treatment of total or partial edentulism through the placement of osseointegrated dental implants
Study: NCT04902898

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Circumcision in adults
Description: Circumcision in adults
Study: NCT01003405

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KUC-7483
Study: NCT04783974

Intervention type: DEVICE
Intervention: Dental implants
Description: Treatment of total or partial edentulism through the placement of osseointegrated dental implants

Intervention type: DEVICE
Intervention: Dental implants
Description: Treatment of total or partial edentulism through the placement of osseointegrated dental implants
Study: NCT06000436

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Cardiovascular disease risk assessment
Description: Cardiovascular disease risk assessment~Training and Consultancy Based on the literature, the researcher prepared a Training Guide for the Prevention of Cardiovascular Diseases, including the subjects of Cardiovascular Diseases and Risk Factors, Physical Activity, Smoking and Heart Health, BMI and Heart Health, Nutrition, and Stress. By using the training guide, training time for individual training intervention will be planned for one day of the week with the participants. Individual training will last 30 minutes at the stops with waiting areas during the working hours of the participants.~Mobile Application To the participants in the intervention group 2, 4. In the 6th and 6th weeks, text messages will be shared once a week to increase motivation and prevent cardiovascular diseases.~Monitoring Daily data from the previous week (cardio score, number of steps) will be taken from the Google Fit application.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cardiovascular disease risk assessment
Description: Cardiovascular disease risk assessment~Training and Consultancy Based on the literature, the researcher prepared a Training Guide for the Prevention of Cardiovascular Diseases, including the subjects of Cardiovascular Diseases and Risk Factors, Physical Activity, Smoking and Heart Health, BMI and Heart Health, Nutrition, and Stress. By using the training guide, training time for individual training intervention will be planned for one day of the week with the participants. Individual training will last 30 minutes at the stops with waiting areas during the working hours of the participants.~Mobile Application To the participants in the intervention group 2, 4. In the 6th and 6th weeks, text messages will be shared once a week to increase motivation and prevent cardiovascular diseases.~Monitoring Daily data from the previous week (cardio score, number of steps) will be taken from the Google Fit application.
Study: NCT06000436

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Training and Consultancy
Description: Based on the literature, the researcher prepared a Training Guide for the Prevention of Cardiovascular Diseases, including the subjects of Cardiovascular Diseases and Risk Factors, Physical Activity, Smoking and Heart Health, BMI and Heart Health, Nutrition, and Stress. Using the training guide, training time for individual training intervention will be planned for one day of the week with the participants. Individual training will last 30 minutes at the stops with waiting areas during the participants' working hours.
Study: NCT06205017

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Foods for Special Medical Purposes
Description: In order to facilitate patient weaning and to improve the enjoyment of foods used in this semi-liquid phase, our Center intends to test Foods for Special Medical Purposes (AFMS) to ensure better nutritional intake, including vitamin D3 and calcium, good palatability, and thus better adherence to the recommended nutritional indications in the immediate postoperative period than the homogenized foods used in the standard diet.
Study: NCT06000436

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mobile Application
Description: To the participants in the intervention group 2, 4. In the 6th and 6th weeks, text messages will be shared once a week to increase motivation and prevent cardiovascular diseases.~Text Messages Week 2 Tobacco use causes 6 million deaths in the world. The risk of death is reduced by 90% in those who stop using tobacco. Alcohol use causes damage to the heart muscle, arrhythmia, and stroke. For a healthy life, you should stay away from smoking and alcohol. ' Week 4 '' Inadequate physical activity increases the risk of death from all causes. Physical activity reduces the risk of hypertension, stroke, and depression. 30 minutes of moderate-intensity physical activity daily is recommended.~Week 6 Adequate consumption of vegetables and fruits reduces the risk of cardiovascular disease. Saturated and trans fats increase the risk of cardiovascular disease. It is recommended to consume \<5 g less per day to prevent cardiovascular diseases.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Monitoring
Description: Daily data from the previous week (cardio score, number of steps) will be taken from the Google Fit application.
Study: NCT06186583

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pimicotinib（ABSK021）
Description: A standard meal should be given to the subjects in the evening before dosing. Then, the subjects should fast for at least 10 hours. Water is not prohibited overnight. The next morning, the subjects should administer study drug in fasted state with warm water. The total volume of warm water and suspension is approximately 240 mL. Water is prohibited from 1 hour before dosing to 1 hour after dosing. No food is allowed within 4 hours after dosing. During the study, subjects will receive standardized meals at approximately the same time each day.
Study: NCT05163314

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Soticlestat
Description: Soticlestat mini-tablets or tablets